Compugen Ltd
NASDAQ:CGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Compugen Ltd
NASDAQ:CGEN
|
IL |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
US |
|
Hanover Foods Corp
OTC:HNFSA
|
US |
Compugen Ltd
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Cash runway: Compugen says its cash (including a $65 million upfront from AstraZeneca) is expected to fund operations into 2029 assuming no further cash inflows.
AstraZeneca deal: Monetized a small portion of future royalties from rilve for $65 million upfront, added $25 million contingent on BLA acceptance, and left total remaining milestones up to €195 million while retaining the majority of royalty economics.
Clinical milestone: COM701 (anti‑PVRIG) expanded globally with U.S., France and Israel sites open; an adaptive trial is maturing with an interim analysis expected in Q1 2027 that could support a maintenance monotherapy path if results are positive.
Partnered program: GS‑0321 (anti‑IL‑13 binding protein) with Gilead is in Phase 1; Gilead paid $60 million upfront plus $30 million at IND clearance, and Compugen is eligible for up to $758 million in milestones plus royalties.
Financial performance: Q4 2025 net profit of $56.8 million ($0.60/share) and FY 2025 net profit of $35.3 million ($0.38/share), driven largely by partnership upfronts and milestone recognition.
Strategy & platform: Company will continue investing in its machine‑based discovery engine and early‑stage pipeline in 2026 while advancing COM701 and supporting GS‑0321 development.
Leadership: Eran Ophir became President & CEO in September 2025 with prior CEO transitioning to Executive Chair, cited as continuity plus operational focus.
